ExCellThera Announces First Patient Treated in Phase I/II Trial of ECT-001 Cell Therapy for Pediatric Patients with High Risk Blood Cancer

By
Justin.choi
-
0
23
ExCellThera Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of ECT-001 for the treatment of pediatric and young adults with high risk myeloid malignancies.
[ExCellThera, Inc. (GlobeNewswire, Inc.)]

Sorry, but the selected Zotpress account can't be found.

Press Release